TY - JOUR
T1 - Association of Posttraumatic Epilepsy with 1-Year Outcomes after Traumatic Brain Injury
AU - Burke, John
AU - Gugger, James
AU - Ding, Kan
AU - Kim, Jennifer A.
AU - Foreman, Brandon
AU - Yue, John K.
AU - Puccio, Ava M.
AU - Yuh, Esther L.
AU - Sun, Xiaoying
AU - Rabinowitz, Miri
AU - Vassar, Mary J.
AU - Taylor, Sabrina R.
AU - Winkler, Ethan A.
AU - Deng, Hansen
AU - McCrea, Michael
AU - Stein, Murray B.
AU - Robertson, Claudia S.
AU - Levin, Harvey S.
AU - Dikmen, Sureyya
AU - Temkin, Nancy R.
AU - Barber, Jason
AU - Giacino, Joseph T.
AU - Mukherjee, Pratik
AU - Wang, Kevin K.W.
AU - Okonkwo, David O.
AU - Markowitz, Amy J.
AU - Jain, Sonia
AU - Lowenstein, Daniel
AU - Manley, Geoffrey T.
AU - Diaz-Arrastia, Ramon
AU - Badjatia, Neeraj
AU - Duhaime, Ann Christine
AU - Feeser, V. Ramana
AU - Gaudette, Etienne
AU - Gopinath, Shankar
AU - Keene, C. Dirk
AU - Korley, Frederick K.
AU - Madden, Christopher
AU - Merchant, Randall
AU - Schnyer, David
AU - Zafonte, Ross
N1 - Funding Information:
Conflict of Interest Disclosures: Dr Foreman reported receiving personal fees from UCB, grants from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS), the Department of Defense (DOD), and National Science Foundation (NSF) outside the submitted work. Dr McCrea reported receiving grants from the University of California, San Francisco, during the conduct of the study and grants from the NIH, DOD, Centers for Disease Control and Prevention (CDC), Abbott Laboratories, National Collegiate Athletic Association (NCAA), and National Football League (NFL) outside the submitted work. Dr Stein reported owning stock in Oxeia Biopharmaceuticals outside the submitted work. Dr Robertson reported receiving grants from the NIH and DOD during the conduct of the study. Dr Temkin reported receiving grants from the NIH and DOD during the conduct of the study. Dr Giacino reported receiving grants from the NIH NINDS and NFL during the conduct of the study. Dr Mukherjee reported receiving grants from the NIH and DOD during the conduct of the study and owning a patent for 15/782,005 (pending University of California Regents) and PCT/US2020/042811 (pending University of California Regents). Ms Markowitz reported receiving grants from the DOD during the conduct of the study. Dr Manley reported receiving grants from the DOD and NIH NINDS during the conduct of the study and grants from NeuroTrauma Sciences, One Mind, and Abbott Laboratories outside the submitted work. Dr Diaz-Arrastia reported receiving grants from the NIH NIHDS and DOD during the conduct of the study. Dr Duhaime reported receiving grants from the NIH during the conduct of the study. Dr Madden reported receiving grants from the NIH during the conduct of the study. Dr Schnyer reported receiving grants from the NIH and DOD during the conduct of the study. Dr Zafonte reported serving on scientific advisory boards for Myomo, OneCare, and Biodirection and as a consultant for the Mackey White committee and the MGH Brain and Body-TRUST Program (funded by the NFL Players Association) and receiving royalties from Springer. No other disclosures were reported.
Funding Information:
Funding/Support: This study was supported by grants from One Mind (Ms Markowitz), NIH NINDS (grant No. U01 NS086090, U54 NS115322 [Dr Diaz-Arrastia], U01 NS114140 [Dr Diaz-Arrastia], and U01 NS086090 [Dr Manley]), DOD (grant No. W81XWH1910861 [Dr Diaz-Arrastia], W81XWH-14-2-0176 [Dr Diaz-Arrastia], W81XWH-14-2-0176 [Dr Manley], and W81XWH-18-2-0042 [Dr Manley]).
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/12/29
Y1 - 2021/12/29
N2 - Importance: Posttraumatic epilepsy (PTE) is a recognized sequela of traumatic brain injury (TBI), but the long-term outcomes associated with PTE independent of injury severity are not precisely known. Objective: To determine the incidence, risk factors, and association with functional outcomes and self-reported somatic, cognitive, and psychological concerns of self-reported PTE in a large, prospectively collected TBI cohort. Design, Setting, and Participants: This multicenter, prospective cohort study was conducted as part of the Transforming Research and Clinical Knowledge in Traumatic Brain Injury study and identified patients presenting with TBI to 1 of 18 participating level 1 US trauma centers from February 2014 to July 2018. Patients with TBI, extracranial orthopedic injuries (orthopedic controls), and individuals without reported injuries (eg, friends and family of participants; hereafter friend controls) were prospectively followed for 12 months. Data were analyzed from January 2020 to April 2021. Exposure: Demographic, imaging, and clinical information was collected according to TBI Common Data Elements. Incidence of self-reported PTE was assessed using the National Institute of Neurological Disorders and Stroke Epilepsy Screening Questionnaire (NINDS-ESQ). Main Outcomes and Measures: Primary outcomes included Glasgow Outcome Scale Extended, Rivermead Cognitive Metric (RCM; derived from the Rivermead Post Concussion Symptoms Questionnaire), and the Brief Symptom Inventory-18 (BSI). Results: Of 3296 participants identified as part of the study, 3044 met inclusion criteria, and 1885 participants (mean [SD] age, 41.3 [17.1] years; 1241 [65.8%] men and 644 [34.2%] women) had follow-up information at 12 months, including 1493 patients with TBI; 182 orthopedic controls, 210 uninjured friend controls; 41 patients with TBI (2.8%) and no controls had positive screening results for PTE. Compared with a negative screening result for PTE, having a positive screening result for PTE was associated with presenting Glasgow Coma Scale score (8.1 [4.8] vs.13.5 [3.3]; P <.001) as well as with anomalous acute head imaging findings (risk ratio, 6.42 [95% CI, 2.71-15.22]). After controlling for age, initial Glasgow Coma Scale score, and imaging findings, compared with patients with TBI and without PTE, patients with TBI and with positive PTE screening results had significantly lower Glasgow Outcome Scale Extended scores (mean [SD], 6.1 [1.7] vs 4.7 [1.5]; P <.001), higher BSI scores (mean [SD], 50.2 [10.7] vs 58.6 [10.8]; P =.02), and higher RCM scores (mean [SD], 3.1 [2.6] vs 5.3 [1.9]; P =.002) at 12 months. Conclusions and Relevance: In this cohort study, the incidence of self-reported PTE after TBI was found to be 2.8% and was independently associated with unfavorable outcomes. These findings highlight the need for effective antiepileptogenic therapies after TBI.
AB - Importance: Posttraumatic epilepsy (PTE) is a recognized sequela of traumatic brain injury (TBI), but the long-term outcomes associated with PTE independent of injury severity are not precisely known. Objective: To determine the incidence, risk factors, and association with functional outcomes and self-reported somatic, cognitive, and psychological concerns of self-reported PTE in a large, prospectively collected TBI cohort. Design, Setting, and Participants: This multicenter, prospective cohort study was conducted as part of the Transforming Research and Clinical Knowledge in Traumatic Brain Injury study and identified patients presenting with TBI to 1 of 18 participating level 1 US trauma centers from February 2014 to July 2018. Patients with TBI, extracranial orthopedic injuries (orthopedic controls), and individuals without reported injuries (eg, friends and family of participants; hereafter friend controls) were prospectively followed for 12 months. Data were analyzed from January 2020 to April 2021. Exposure: Demographic, imaging, and clinical information was collected according to TBI Common Data Elements. Incidence of self-reported PTE was assessed using the National Institute of Neurological Disorders and Stroke Epilepsy Screening Questionnaire (NINDS-ESQ). Main Outcomes and Measures: Primary outcomes included Glasgow Outcome Scale Extended, Rivermead Cognitive Metric (RCM; derived from the Rivermead Post Concussion Symptoms Questionnaire), and the Brief Symptom Inventory-18 (BSI). Results: Of 3296 participants identified as part of the study, 3044 met inclusion criteria, and 1885 participants (mean [SD] age, 41.3 [17.1] years; 1241 [65.8%] men and 644 [34.2%] women) had follow-up information at 12 months, including 1493 patients with TBI; 182 orthopedic controls, 210 uninjured friend controls; 41 patients with TBI (2.8%) and no controls had positive screening results for PTE. Compared with a negative screening result for PTE, having a positive screening result for PTE was associated with presenting Glasgow Coma Scale score (8.1 [4.8] vs.13.5 [3.3]; P <.001) as well as with anomalous acute head imaging findings (risk ratio, 6.42 [95% CI, 2.71-15.22]). After controlling for age, initial Glasgow Coma Scale score, and imaging findings, compared with patients with TBI and without PTE, patients with TBI and with positive PTE screening results had significantly lower Glasgow Outcome Scale Extended scores (mean [SD], 6.1 [1.7] vs 4.7 [1.5]; P <.001), higher BSI scores (mean [SD], 50.2 [10.7] vs 58.6 [10.8]; P =.02), and higher RCM scores (mean [SD], 3.1 [2.6] vs 5.3 [1.9]; P =.002) at 12 months. Conclusions and Relevance: In this cohort study, the incidence of self-reported PTE after TBI was found to be 2.8% and was independently associated with unfavorable outcomes. These findings highlight the need for effective antiepileptogenic therapies after TBI.
UR - http://www.scopus.com/inward/record.url?scp=85122830323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122830323&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2021.40191
DO - 10.1001/jamanetworkopen.2021.40191
M3 - Article
C2 - 34964854
AN - SCOPUS:85122830323
SN - 2574-3805
VL - 4
JO - JAMA Network Open
JF - JAMA Network Open
IS - 12
M1 - P03.123
ER -